Publication title: “Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of…
CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression-Free Survival and…
ROCKAWAY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today…
Based on previously reported positive Phase 1 results, Kynexis is advancing KYN-5356, a first-in-class KAT-II inhibitor, into a Phase 2…
BOSTON, Sept. 30, 2025 /PRNewswire/ -- BrainCo holds that the true value of technology lies in expanding the boundaries of…
MIDDLETON, Wis., Sept. 30, 2025 /PRNewswire/ -- Natus Medical Incorporated, the largest global pure-play neurodiagnostics company, today announced it has…
First and Only REN-Based Migraine Treatment Approved in China BEIJING and NETANYA, Israel, Sept. 29, 2025 /PRNewswire/ -- Pier 88 Health, a…
CLINICAL study SHOWS DETECTION OF CTCs in glioblastoma PatientsGBM CTC isolation only possible with Parsortix label-free methodologyData presented at the…
DTSS Achieves Fourth Quarter Net Income Breakeven Driven byCutting-Edge Acoustics and AI Multimodal Digitalization; Ongoing Commercialization Updates in the Coming Weeks BEIJING,…
FREDERICK, Md., Sept. 26, 2025 /PRNewswire/ -- For more than 30 years, Lou Manfredini—better known as Mr. Fix-It—has been America's trusted…